Dupilumab, a fully human monoclonal antibody that inhibits interleukin IL-4 and IL-13 signaling, has been approved for the treatment of chronic spontaneous urticaria (CSU) in patients inadequately controlled by histamine-1 antihistamines. It is the first targeted therapy approved for CSU in over a decade and has shown significant reductions in itch severity and urticaria activity scores in phase III trials. The approval provides a new option for patients with CSU and adds to the list of approved indications for dupilumab in type 2 inflammatory conditions.

Source: Regeneron Pharmaceuticals